Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ALTHX.PA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.19
N/A
-0.78
vs -1.04
Q2.20
N/A
-0.80
vs -0.90
Q4.20
N/A
-0.47
vs -0.78
Q2.21
N/A
-0.81
vs -0.80
Q4.21
N/A
-0.81
vs -0.47
Q2.22
N/A
-0.62
vs -0.81
Q4.22
N/A
-0.62
vs -0.81
Q2.23
N/A
-0.69
vs -0.62
Q4.23
N/A
-0.41
vs -0.62
Q2.24
+102%
0.01
vs -0.69
Sales Growth
YoY
Current
Estimates
Q4.19
-79%
9.9K vs 47.7K
Q2.20
-50%
278.9K vs 553.9K
Q4.20
+58%
15.7K vs 9.9K
Q2.21
-99%
1.8K vs 278.9K
Q4.21
-108%
-1220.00 vs 15.7K
Q2.22
+22548%
412.7K vs 1.8K
Q4.22
+284%
2.2K vs -1220
Q2.23
-41%
244.3K vs 412.7K
Q4.23
+3226%
74.7K vs 2.2K
Q2.24
+806%
2.2M vs 244.3K
Return on Equity
QoQ
Q4.20
-22%
-0.22
vs -0.44
Q2.21
-32%
-0.32
vs -0.22
Q4.21
-43%
-0.43
vs -0.32
Q2.22
-36%
-0.36
vs -0.43
Q4.22
-57%
-0.57
vs -0.36
Q2.23
-138%
-1.38
vs -0.57
Q4.23
+367%
3.67
vs -1.38
Q2.24
-2923%
-29.23
vs 3.67
Institutionnal Ownership
Quote Panel
Key Metrics
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.
PAR
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.05Â ( -4.00%)
Relative Strenght
Volume Buzz
-71%
Earning Acce
Yes
Dist 52w H.
29%Relative Strength
ALTHX.PA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ALTHX.PA compares to sector?
Forecast
-91%2025-Revenue
3197%2025-EPS
-9%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available